Research Interests
Host-Pathogen interactions, Microbial signal transduction, Tuberculosis
Research Focus Teams
COVID-19, Tuberculosis, Lung Disease
Departments
Infectious diseases, Microbiology & Immunology
Contact
Email: yossi[at]mail.ubc.ca
Office Phone: 604–822–3432
Office number: 2503
Publications
Lab Website
Dr. Yossef Av-Gay is a professor of Microbiology and Infectious Diseases in the Faculty of Medicine. He is also an associate member of the Department of Microbiology and Immunology and holds an adjunct professorship at the medical school of Ben Gurion University of the Negev, Israel. A microbiologist by training, his research interests lie with microbial disease mechanisms causing chronic lung infections, primarily tuberculosis (TB), followed by nontuberculous mycobacteria (NTM) diseases . He explores molecular events that govern host-pathogen interactions and the ability of mycobacteria to block the immune response to infection. Dr. Av-Gay’s research is geared towards the identification and characterization of novel drugs and drug targets in Mycobacterium tuberculosis. Dr. Av-Gay’s most significant discovery was the identification and characterization of PtpA, a protein phosphatase in Mtb which inhibits the normal macrophage response to infection.
Prof. Av-Gay received his BSc in Biology, MSc in Microbiology, and PhD in Microbial Genetics – all from Tel Aviv University, Tel Aviv, Israel, and advanced training at John Innes Institute, Norwich, UK, Albert Einstein Collage of Medicine, New York and UBC Microbiology.
Prof. Av-Gay authored over 100 peer review scientific publications, review articles, book chapters and 15 patents. Prof. Av-Gay served as an editor for the Journal of Biological Chemistry (2010-2015), and on scientific advisory boards of several biotechnology companies. Prof. Av-Gay is a member of the scientific review panels of the Canadian Institute of Health Research (Microbiology and Infectious Disease (2009-2016) and Foundation and Project Grants (2016-) , the French Agence Nationale de la Recherche, Innovative Medicine Innovations, The UK welcome Trust, US National Institute of Health, and the European Commission FP6, FP7 and Horizon 2020 programs.
The Av-Gay Lab was established at the University of British Columbia in 1997. Our primary research focus is Tuberculosis (TB) pathogenesis.
TB is caused by Mycobacterium tuberculosis, which is one of the most devastating infectious agents in the world today. One-third of the world’s population is exposed to TB, which kills nearly two million people annually with over 10 million new infections taking place each year. Synergy with the human immunodeficiency virus (commonly known as HIV), along with the emergence of multidrug resistant strains of TB, has reaffirmed TB as a tremendous public health threat worldwide today.
Our lab is engaged in both basic and translational research emphasizing mycobacterial genetics and biochemistry with the aim to develop new drugs in collaboration with industry and other academic groups. Our focus is primarily in tuberculosis (TB) research, studying signal transduction in Mycobacterium tuberculosis (Mtb) and understanding the intracellular lifestyle of Mtb in order to develop new and better drugs that can target Mtb in its natural environment in the host.
We are also developing new screening methods to identify novel drugs against the nontuberculous mycobacterial (NTM) cystic fibrosis pathogen, M. abscessus. Finally, we have developed a nitric oxide inhalation therapy that is undergoing clinical trials for the treatment of lung infections.